Company will continue to manufacture and ship innovative products for global development and research throughout crisis HOLLISTON, Mass. , March 23, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) has launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) – 

Substantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets HOLLISTON, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline issued earlier today by Harvard Bioscience, Inc.

Substantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets HOLLISTON, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three and twelve months ended

HOLLISTON, Mass. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2019 before the market opens on February 26, 2020 , and will hold a conference call to discuss the results on February 26, 2020 at

HOLLISTON, Mass. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green , Chairman, President and CEO, and Michael Rossi , CFO will attend The Benchmark Company’s 8th Annual Discovery One-on-One Conference to be held on December 4, 2019 at the

Improves adjusted operating margins while taking actions to underpin next year’s profit and growth targets Q3 Revenue of $27.4 million Q3 Operating Loss (GAAP) of $(1.4) million ; Adjusted Operating Income (Non-GAAP) of $3.3 million Q3 GAAP EPS of $(0.07) ; Adjusted Diluted EPS (Non-GAAP) of $0.04

HOLLISTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecular Technologies on October 31, 2019 , the Compensation Committee of the Board of Directors approved

HOLLISTON, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green .  Singh will lead the newly formed Cellular

HOLLISTON, Mass. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its quarterly results for third quarter ended September 30, 2019 after market close on November 5, 2019 and hold a conference call to discuss the results for the third quarter on November 5,

HOLLISTON, Mass. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green .